{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:44:51Z","timestamp":1790286291990,"version":"4.1.0"},"reference-count":13,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroendocrinology"],"published-print":{"date-parts":[[2022]]},"abstract":"<b><i>Introduction:<\/i><\/b> The overexpression of somatostatin receptor type 2 (SSTR2) is a unique characteristic of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), which establishes the basis for both diagnosis and therapy. The SSTR status can be evaluated by immunohistochemical staining (IHC) and <sup>68<\/sup>Ga-DOTATATE positron emission tomography\/computed tomography (PET\/CT) imaging. This study attempted to determine the relationship between IHC and <sup>68<\/sup>Ga-DOTATATE PET\/CT imaging and to explore the optimal cutoff value for SSTR IHC reading. <b><i>Patients and Methods:<\/i><\/b> A total of 100 GEP-NENs with SSTR PET\/CT and pathological data were retrospectively analyzed, which consisted of neuroendocrine tumor (NET) G1 (<i>n<\/i> = 9), NET G2 (<i>n<\/i> = 64), NET G3 (<i>n<\/i> = 13), neuroendocrine carcinoma ( <i>n<\/i> = 10), and mixed neuroendocrine-non-NENs ( <i>n<\/i> = 4). SSTR2-IHC results were interpreted by 4 well-established semiquantitative scoring systems, including human epidermal growth factor receptor 2 (HER2) score, Volante score, H score, and immunoreactive score. <b><i>Results:<\/i><\/b> In the homogeneous SSTR2 expression group (accounting for 57% of all cases), the 4 scoring systems were highly concordant with each other (Kendall\u2019s Tau-b coefficient range: 0.80\u20130.96, <i>p<\/i> &#x3c; 0.001) and also highly correlated with the <sup>68<\/sup>Ga-DOTATATE PET\/CT imaging results (Spearman\u2019s rank correlation coefficients: 0.71, 0.86, 0.80, and 0.71, <i>p<\/i> &#x3c; 0.001). In the heterogeneous group (43%), the 4 scoring systems revealed a lower level of concordance (the Kendall Tau-b coefficient range: 0.40\u20130.75, <i>p<\/i> &#x3c; 0.01), and the correlation with <sup>68<\/sup>Ga-DOTATATE PET\/CT imaging was also lower, albeit statistically significant (Spearman\u2019s rank correlation coefficients: 0.53, 0.38, 0.36, and 0.33, <i>p<\/i> &#x3c; 0.05). Heterogeneous SSTR2 expression was mainly observed in the HER2 2+ cases, for which the combination with H score could help identify positive cases with increased sensitivity and specificity. The highest sensitivity and specificity of H scores in predicting the imaging results were achieved at 86.10 and 89.30% when defining the cutoff value as 160, indicating that 80% of the tumor cells were moderately positive or 55% were strongly positive. <b><i>Conclusions:<\/i><\/b> SSTR2 IHC was found to predict <sup>68<\/sup>Ga-DOTATATE PET\/CT imaging accurately, especially in the homogeneous expression group. According to the positive <sup>68<\/sup>Ga-DOTATATE PET\/CT outcomes, 80% of the tumor cells moderately positive or 55% strongly positive was the cutoff values for SSTR2-IHC reading. <\/jats:p>","DOI":"10.1159\/000517530","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T21:03:04Z","timestamp":1622667784000},"page":"358-369","source":"Crossref","is-referenced-by-count":18,"title":["Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with <sup>68<\/sup>Ga-DOTATATE Positron Emission Tomography\/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms"],"prefix":"10.1159","volume":"112","author":[{"given":"Jiangyuan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinya","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2017.11.008"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800954"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/his.12662"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(89)91258-0"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-017-2093-3"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/his.12662"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04439-9"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12775"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31823d07f3"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1846-5"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2001.01084.x"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.069"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0944-5"}],"container-title":["Neuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/517530","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/517530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:06:16Z","timestamp":1745420776000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000517530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,2]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,3,22]]},"published-print":{"date-parts":[[2022,3,29]]}},"URL":"https:\/\/doi.org\/10.1159\/000517530","archive":["Portico"],"relation":{},"ISSN":["0028-3835","1423-0194"],"issn-type":[{"value":"0028-3835","type":"print"},{"value":"1423-0194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,2]]}}}